AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Brief Report | Open Access

Clinical and multimodal imaging characteristics of acute central serous chorioretinopathy with fibrinous exudation

Ze-Chen Liu1Jie Zhang2Jin-Dong Han1( )
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300384, China
Department of Ophthalmology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China

Co-first Authors: Ze-Chen Liu and Jie Zhang

Show Author Information

Abstract

AIM

To analyze the clinical and multimodal imaging characteristics of acute central serous chorioretinopathy (CSC) with or without fibrinous exudation.

METHODS

Retrospective case-control study. Patients diagnosed with acute CSC with fibrinous exudation (FE group) and without fibrinous exudation (non-FE group) were consecutively included. The clinical data and multimodal images including color fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography (OCT), fundus fluorescein angiography, and indocyanine green angiography at presentation were recorded. Treatment method, follow-up outcomes including best-corrected visual acuity (BCVA) and OCT characteristics were also documented.

RESULTS

The FE group (n=8, 8 eyes, 6 males) had a mean age of 47.50±7.27y, and the median symptom duration was 26.50d. The non-FE group (n=20, 20 eyes, 16 males) had a mean age of 40.40±4.36y, and the median symptom duration was 7.00d. Compared to the non-FE group, the FE group exhibited significantly older age (P=0.004), longer self-reported symptom duration (P=0.02), and poorer baseline and follow-up BCVA (P=0.011, P=0.003). After more than one month follow-up, visual improvement was statistically significant in the non-FE group (P=0.017), but not in the FE group (P=0.157). Multimodal imaging results found higher prevalence of pigment epithelial detachment (PED; P=0.029) and larger subfoveal choroidal thickness (P<0.001) in the FE group, while there was no significant difference in central macular thickness between the groups. The leakage start time was earlier in the FE group (14.50±2.33s) than in the non-FE group (22.67±1.24s, P<0.001). The expanding dot sign was the most common leakage pattern of fibrinous CSC. Late leakage area usually expanded to more than 1/2 disc diameter (DD) in the FE group, while it was less than 1/2 DD in the non-FE group.

CONCLUSION

Fibrinous exudation in acute CSC is a multimodal imaging biomarker indicative of severe choroidal vasculopathy and retinal pigment epithelium barrier failure. Recognizing this entity and understanding its potential mechanisms are crucial for managing patient prognosis and may guide future targeted interventions.

References

【1】
【1】
 
 
International Journal of Ophthalmology
Pages 819-826

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Liu Z-C, Zhang J, Han J-D. Clinical and multimodal imaging characteristics of acute central serous chorioretinopathy with fibrinous exudation. International Journal of Ophthalmology, 2026, 19(4): 819-826. https://doi.org/10.18240/ijo.2026.04.23

137

Views

9

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 20 September 2025
Accepted: 18 November 2025
Published: 18 April 2026
© 2026 International Journal of Ophthalmology Press

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).